Background: Adding mFOLFOX6 (folinic acid, fluorouracil, oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response. Objective: To analyze disease-free and overall survival. Design: Nonrandomized phase II trial. Settings: Multi-institutional. Patients: Four sequential study groups with stage II or III rectal cancer. Intervention: All patients received 50 Gy of radiation with concurrent continuous infusion of fluorouracil for 5 weeks. Patients in each group received 0, 2, 4, or 6 cycles of mFOLFOX6 after chemoradiation and before total mesorectal excision. Patients were recommended to receive adjuvant chemotherapy after surgery to complete a total of 8 cycles of mFOLFOX6. Main outcome measures: The trial was powered to detect differences in pathological complete response, which was reported previously. Disease-free and overall survival are the main outcomes for the current study. Results: Of 259 patients, 211 had a complete follow-up. Median follow-up was 59 months (range, 9-125). The mean number of total chemotherapy cycles differed between the four groups (P = 0.002), as one third of patients in the group assigned to no preoperative FOLFOX did not receive any adjuvant chemotherapy. Diseasefree survival was significantly associated with study group, ypTNM stage, and pathological complete response (P = 0.004, <0.001 and 0.001, respectively). A secondary analysis including only patients who received at least one cycle of FOLFOX still showed differences in survival between study groups (P = 0.03). Conclusions: Adding mFOLFOX6 after chemoradiotherapy and before total mesorectal excision increases compliance with systemic chemotherapy and disease-free survival in patients with locally advanced rectal cancer. Neoadjuvant consolidation chemotherapy may have benefits beyond increasing pathological complete response rates. 
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JSCP Visiting Paper
Purpose: The aim of this study is to evaluate the lymphatic flow at the splenic flexure.
Methods: From July 2013 to June 2017, we enrolled consecutive patients of colon cancer located in splenic flexure with preoperative diagnosis of clinical N0. Primary outcome is frequency of the direction of lymphatic flow from splenic flexure. At first, we injected indocyanine green (2.5mg) to submucosal layer near the tumor and observed lymphatic flow using the laparoscopic near-infrared camera system in 30 minutes after injection.
Results: A total of 44consecutive patients were enrolled in this study. These patients included 12females, and had a mean age of 69years, a mean body mass index of 23.2kg/m2.A mean duration of operation was 200minutes and a mean blood loss was 37ml. The presence of accessory left colic artery (dalca)rate was 34% (15cases). The prevalence of direction of lymph flow type was 13cases (29.5%) for left colic artery (LCA)area, 6cases (13.6%) for LCA and Alcanareas, 9cases (20.5%) for middle colic artery (MCA)area, 5cases (11.4%) for dalcaarea, 4cases(9.1%) for MAC and aceareas. Lymph flow not accompanying artery directed to the root of IMV was 5-cases (11.4%). 0 case (0.0%) for both LCA and MCA areas. There are 27cases (61.4%) with lymph flow directed to the area of root of IMV if Alcanexist or not. Number of retrieved lymph nodes (LNs) was 17.3and fluorescence LNs was 10.4. LN metastases were observed in 9cases(20.5%), andall the involved LNs existed in lymph flow areas determined by the fluorescence lymphatic flow evaluation. Conclusion: In CME and CVL for colon cancer located in splenic flexure, we should perform LN dissection of the root of IMV area plus LCA area or MCA area by the fluorescence lymphatic flow evaluation, and LN dissection of 3 areas is not necessary.
KSCP Visiting Paper
Reduced-port robotic-versus multi-port laparoscopic surgery for left-sided colon cancer: clinicopathologic outcomes and patient scar assessment Sung Uk Bae, Woon Kyung Jeong & Seong Kyu Baek Department of Surgery, School of Medicine, Keimyung University and Dongsan Medical Center, Daegu, Korea
Objectives: The aim of our study was to compare the clinicopathologic outcomes and patient-reported body image and cosmesis assessment between the single-port plus one conventional robotic port, a reduced port robotic surgery (RPRS) and multi-port laparoscopic surgery (MPLS) for colon cancer. Methods: The study group included 36 patients who underwent a RPRS and 61 patients who underwent a MPLS for colon cancer between August 2014 and February 2018.
Results: The median operative time was significantly longer in the RPRS group than in the MPLS group (RPRS: 232 vs. MPLS: 155 minutes, P < 0.001). One patient (3.1%) required a conversion from RPRS to reduce-port laparoscopic surgery. There were no apparent differences in the time taken to return of normal bowel function, tolerance of diet, length of hospital stay, and pain score, which was measured on the numeric rating scale on postoperative day 1 and 2, but the RPRS group had a significantly shorter time taken to urinary catheter removal (2 vs. 2 days, P = 0.029) and smaller total incision length (5.0 cm vs. 8.0 cm, <0.001).
The median proximal and distal resection margins and median number of harvested lymph nodes between two groups were similar. There were no significant differences in the rate of postoperative complications between the groups (16.7% in the RPRS group and 23.0% in the MPLS group, P = 0.460). There were significant differences in appearance (15 vs. 18, P < 0.001), consciousness (9 vs. 10, P = 0.001), satisfaction with appearance (16 vs. 16, P < 0.001), satisfaction with symptoms (10 vs. 10, P = 0.008) and overall score (49 vs. 55, P < 0.001), all favoring the reduced-port robotic approach. Conclusions: We demonstrated the short-term oncologic safety and cosmetic benefit of RPRS for left-sided colon cancer. 
